AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Summary
Third Opinion Trial Synopsis:
AMG 176 is a medicine that doctors are testing to see if it's safe and easy for people with certain types of cancer to use. They found that even the smallest amount of the medicine is safe for people with multiple myeloma or acute myeloid leukemia who have had cancer come back or not respond to other treatments.
AMG 176 is a medicine that doctors are testing to see if it's safe and easy for people with certain types of cancer to use. They found that even the smallest amount of the medicine is safe for people with multiple myeloma or acute myeloid leukemia who have had cancer come back or not respond to other treatments.
*Third Opinion AI Generated Synopsis
Trial Summary
At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia
At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: